Tumor Immune Evasion and Pembrolizumab

How does the PD-1/PD-L1 pathway contribute to tumor immune evasion, and how does pembrolizumab interrupt it?

The PD-1/PD-L1 pathway enables tumors to evade immune destruction by suppressing T cell cytolytic activity, inducing T cell exhaustion, and creating adaptive immune resistance through interferon-driven PD-L1 upregulation, while pembrolizumab interrupts this pathway by blocking PD-1/PD-L1 interaction to restore T cell proliferation and effector function, resulting in intratumoral CD8+ T cell expansion and durable tumor regression in 18-76% of patients depending on tumor type and baseline immune infiltration.

Abstract

The PD-1/PD-L1 pathway enables tumor immune evasion through multiple mechanisms: direct suppression of T cell function by inhibiting cytokine production and cytolytic activity, induction of T cell exhaustion, and adaptive immune resistance whereby interferon production by tumor-infiltrating CD8+ cells upregulates PD-L1 expression. This interaction dampens T cell proliferation and activation, blocks effector functions, and creates an immunosuppressive tumor microenvironment through upregulation of genes involved in extracellular matrix remodeling and metabolic changes favoring immune evasion. Some CD8+ T cells enter an irreversible dysfunctional state that cannot be rescued by pathway blockade.

Pembrolizumab interrupts this pathway by blocking PD-1 interaction with PD-L1 and PD-L2, removing the suppressive effect on T-cell proliferation and immune response. This blockade restores T cell function, leading to increased proliferation of intratumoral CD8+ T cells that directly correlates with tumor size reduction, expansion of memory CD8+ T cells, enhanced effector function marked by granzyme B expression, and development of a more clonal TCR repertoire. Clinical evidence across 10 sources demonstrates objective response rates of 18-76% depending on tumor type and treatment regimen, with responses lasting >1 year in most responders. Pre-existing CD8+ T cells at the invasive tumor margin with close proximity between PD-1 and PD-L1 expressing cells predict response, while higher PD-L1 expression (≥50%) and high tumor mutational burden correlate with improved response rates, though responses occur in PD-L1-negative tumors.

Methods

We analyzed 10 sources from an initial pool of 200, using 9 screening criteria. Each paper was reviewed for 9 key aspects that mattered most to the research question.

Records from Elicit search

• n = 200

• Papers screened using: PD-1/PD-L1 Pathway Focus, Clinical Relevance, Study Design, Relevant Outcomes, Pembrolizumab or PD-1/PD-L1 Inclusion, Beyond Pharmacokinetics, Adequate Sample Size, Human System Validation, Publication Type

• n = 200

• Papers screened out

• n = 190

• Papers included for extraction

• n = 10

Data extraction

We asked a large language model to extract each data column below from each paper. We gave the model the extraction instructions shown below for each column.

Study Design

• Study design and basic methodology.
  • Study design (clinical trial, mechanistic study, observational, etc.)
  • Sample size and patient population
  • Methods used (flow cytometry, immunohistochemistry, sequencing, etc.)
  • Study duration and follow-up period

Cancer Types

• Specific cancer types and patient populations studied in relation to PD-1/PD-L1 immune evasion and pembrolizumab treatment.
  • Primary cancer type(s)
  • Disease stage (early, advanced, metastatic)
  • Prior treatment status
  • Any cancer-specific characteristics relevant to PD-1/PD-L1 pathway function

PD-1/PD-L1 Immune Evasion Mechanisms

• Mechanisms by which the PD-1/PD-L1 pathway contributes to tumor immune evasion.
  • How PD-1/PD-L1 interaction suppresses immune responses
  • Effects on T cell function, proliferation, and activation
  • Role in adaptive immune resistance
  • Impact on other immune cell types
  • Molecular pathways and signaling cascades involved
  • Tumor microenvironment changes that promote immune evasion

Pembrolizumab Interruption Mechanisms

• Mechanisms by which pembrolizumab interrupts the PD-1/PD-L1 immune evasion pathway.
  • How antibody binding blocks PD-1/PD-L1 interaction
  • Restoration of T cell function and activation
  • Changes in immune cell trafficking and infiltration
  • Reversal of immune suppression mechanisms
  • Molecular and cellular changes that demonstrate pathway interruption
  • Differences between anti-PD-1 vs anti-PD-L1 approaches

Immune Cell Changes

• Changes in immune cell populations and function during pembrolizumab treatment.
  • Changes in CD8+ and CD4+ T cell numbers, phenotypes, and function
  • Memory T cell expansion and activation status
  • Changes in regulatory T cells, B cells, NK cells, myeloid cells
  • Immune cell infiltration into tumors
  • T cell receptor diversity and clonality changes
  • Functional assays showing restored immune activity

Biomarker Evidence

• Biomarker data that demonstrates PD-1/PD-L1 pathway activity and its interruption by pembrolizumab.
  • PD-1 and PD-L1 expression levels (baseline and on-treatment)
  • Spatial distribution of PD-1/PD-L1 expressing cells in tumors
  • Other immune checkpoint molecule expression
  • Inflammatory markers and cytokine profiles
  • Tumor mutational burden and neoantigen load
  • Molecular signatures of pathway activity or blockade

Clinical Evidence

• Clinical outcome data that serves as evidence of successful PD-1/PD-L1 pathway interruption by pembrolizumab.
  • Objective response rates (complete and partial responses)
  • Duration of responses and progression-free survival
  • Overall survival data
  • Disease control rates and stable disease
  • Time to response and durability metrics
  • Correlation between clinical outcomes and mechanistic evidence of pathway interruption

Predictive Factors

• Factors that predict response or resistance to pembrolizumab treatment.
  • Baseline PD-L1 expression as predictor of response
  • Immune cell infiltration patterns predicting response
  • Genetic or molecular features associated with response/resistance
  • Patient characteristics affecting pathway blockade efficacy
  • Mechanisms of primary or acquired resistance to PD-1/PD-L1 blockade
  • Biomarkers that correlate with successful pathway interruption

Safety Profile

• Safety and toxicity data related to pembrolizumab treatment and PD-1/PD-L1 pathway blockade.
  • Immune-related adverse events and their frequencies
  • Grade 3/4 toxicities and serious adverse events
  • Autoimmune toxicities resulting from pathway interruption
  • Treatment discontinuation rates due to adverse events
  • Management strategies for immune-related toxicities
  • Relationship between toxicity profiles and successful pathway blockade

Results

Characteristics of Included Studies

The review included 10 sources published between 2012 and 2020, comprising 5 primary clinical studies, 4 review articles, and 1 literature review. Four sources were available only as abstracts.

Study Overview:

Mechanisms of PD-1/PD-L1 Pathway in Tumor Immune Evasion

Suppression of T Cell Function

The PD-1/PD-L1 pathway serves as a critical immune checkpoint that tumors exploit to evade host immunity. PD-1/PD-L1 interaction suppresses immune responses by reducing T-lymphocyte function and inhibiting cytokine production and cytolytic activity of PD-1-positive, tumor-infiltrating CD4+ and CD8+ T cells. This interaction dampens T cell function and proliferation, blocks effector functions, and reduces T cell killing capacity.

Adaptive Immune Resistance

A key mechanism of immune evasion involves adaptive immune resistance, where PD-L1 expression is upregulated in response to immune attack. Production of interferons by tumor-infiltrating CD8+ cells can induce PD-L1 expression, creating a negative feedback loop.

Tumor Microenvironment Effects

Tumors create an immunosuppressive microenvironment through multiple mechanisms. PD-L1 is abnormally expressed by tumor cells and lymphocytes in the tumor microenvironment, enhancing tumorigenesis and making tumor cells less susceptible to T-cell mediated lysis.

Mechanisms by Which Pembrolizumab Interrupts the PD-1/PD-L1 Pathway

Antibody-Mediated Blockade

Pembrolizumab is a highly selective monoclonal antibody designed to block the interaction of PD-1 with its ligands PD-L1 and PD-L2. By preventing PD-1 from binding to PD-L1, pembrolizumab removes the suppressive effect on T-cell proliferation and immune response.

Restoration of Immune Cell Function

Following PD-1 blockade, significant changes occur in immune cell populations and function. CD8+ T cells show increased proliferation within tumors, with responding patients demonstrating increased Ki67 positivity indicating active proliferation and elevated granzyme B expression indicating enhanced effector function.

Spatial and Temporal Dynamics

Pre-treatment samples from responding patients showed higher numbers of CD8+, PD-1-, and PD-L1-expressing cells at the invasive tumor margin, with close proximity between PD-1 and PD-L1 cells at the invasive tumor margin.

Clinical Evidence of Pathway Interruption

Response Rates Across Cancer Types

Clinical trials demonstrated substantial objective response rates across multiple cancer types.

Duration and Durability of Responses

Responses to PD-1/PD-L1 blockade demonstrated remarkable durability. In the anti-PD-1 trial, many responses lasted 1 year or more.

Biomarker Correlations

PD-L1 expression emerged as a predictive biomarker, though with limitations.

Safety Profile

Immune-Related Adverse Events

PD-1/PD-L1 blockade demonstrated a more favorable safety profile compared to previous immunotherapies.

Management Strategies

Management of immune-related toxicities involved glucocorticoids and replacement therapy.

Synthesis

The body of evidence demonstrates a coherent mechanistic and clinical narrative for how pembrolizumab interrupts the PD-1/PD-L1 immune evasion pathway. Response rates correlate with specific tumor characteristics. The durability of responses contrasts with the CD8+ T cell exhaustion described in the mechanistic studies, suggesting pathway blockade catches tumors before irreversible T cell dysfunction occurs.